Partners

The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.

Coordinating organizations:

University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL coordinates the processing of register data.

Funded by:

and the funding research partners:

AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.

In cooperation with the Finnish Biobank cooperative FINBB and these Finnish biobanks:

Biobank	The background organization that has signed the consortium agreement for the biobank	Biobank logo
Auria Biobank	Wellbeing Services County of Southwest Finland University of Turku
Northern Finland Biobank Borealis	Wellbeing Services County of North Ostrobothnia University of Oulu
Arctic Biobank	University of Oulu
Central Finland Biobank	Wellbeing Services County of Central Finland University of Jyväskylä
Finnish Clinical Biobank Tampere	Wellbeing Services County of Pirkanmaa Tampere University Foundation sr
Biobank of Eastern Finland	Wellbeing Services County of North Savo University of Eastern Finland
Helsinki Biobank	HUS, University of Helsinki
THL Biobank	The Finnish Institute for Health and Welfare
FRC Blood Service Biobank	The Finnish Red Cross Blood Service
FHRB Biobank	Finnish Association of Haematology
Finnish Biobank Cooperative (FINBB)